TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly

• Published in: Biomedicines Vol. 12; no. 6; p. 1277
• Main Authors: Miura, Katsuhiro, Nishimaki-Watanabe, Haruna, Takahashi, Hiromichi, Nakagawa, Masaru, Otake, Shimon, Hamada, Takashi, Koike, Takashi, Iizuka, Kazuhide, Takeuchi, Yuuichi, Kurihara, Kazuya, Endo, Toshihide, Ito, Shun, Nukariya, Hironao, Namiki, Takahiro, Hayashi, Yoshiyuki, Nakamura, Hideki
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.06.2024; MDPI
• Subjects: Biomarkers; Biopsy; Cancer; Castleman's disease; Chemotherapy; Collaboration; Corticosteroids; Cytotoxicity; Development and progression; Diagnosis; Disease; Edema; Evidence-based medicine; Fever; Fibrosis; idiopathic multicentric Castleman disease; Inflammatory diseases; Interleukin 6; Interleukins; Kidney failure; Lymph nodes; Lymphatic system; Lymphoma; Medical research; Medicine, Experimental; Patients; Pharmaceutical industry; Renal insufficiency; Review; siltuximab; TAFRO syndrome; Thrombocytopenia; tocilizumab; Tuberculosis; Vincristine; United States; Japan; TAFRO syndrome; idiopathic multicentric Castleman disease; siltuximab; tocilizumab; interleukin-6
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12061277

TAFRO syndrome is an inflammatory disorder of unknown etiology characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly. Despite great advancements in research on the TAFRO syndrome in the last decade, its diagnosis and treatment are still challenging for most clinicians because of its rarity and severity. Since the initial proposal of the TAFRO syndrome as a distinct disease entity in 2010, two independent diagnostic criteria have been developed. Although these are different in the concept of whether TAFRO syndrome is a subtype of idiopathic multicentric Castleman disease or not, they are similar except for the magnitude of lymph node histopathology. Because there have been no specific biomarkers, numerous diseases must be ruled out before the diagnosis of TAFRO syndrome is made. The standard of care has not been fully established, but interleukin-6 blockade therapy with siltuximab or tocilizumab and anti-inflammatory therapy with high-dose corticosteroids are the most commonly applied for the treatment of TAFRO syndrome. The other immune suppressive agents or combination cytotoxic chemotherapies are considered for patients who do not respond to the initial treatment. Whereas glowing awareness of this disease improves the clinical outcomes of patients with TAFRO syndrome, further worldwide collaborations are warranted.